Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VB-111 + Bevacizumab in Recurrent Glioblastoma
NCT02511405Phase 3Completed
- Sponsor
- VBL Therapeutics
- Start
- Aug 2015
- Primary completion
- Nov 2017
- Modality
- Gene Editing, Gene Silencing, Oncolytic Viruses
- Countries
- 3
01
Overview
A Phase 3 trial of ofranergene obadenovec in glioblastoma (GBM), sponsored by VBL Therapeutics. Started Aug 2015; status: completed.
02
Drugs
ofranergene obadenovec
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT02511405.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02511405.